How It Works:
Epsilon aminocaproic acid competitively inhibits activation of plasminogen, thereby reducing conversion of plasminogen to plasmin (fibrinolysin), an enzyme that degrades fibrin clots as well as fibrinogen and other plasma proteins including the procoagulant factors V and VIII. Epsilon aminocaproic acid also directly inhibits plasmin activity, but higher doses are required than are needed to reduce plasmin formation.
watery eyes., Decreased urination, renal failure, staffy nose, nausea and vomiting, skin rash, thromboemolism, unusual tiredness, dizziness, hypotension, stomach cramps, headache, myopathy
Epsilon aminocaproic acid is indicated for treatment of severe bleeding that may occur following heart surgery (with or without cardiac bypass procedures) and portacaval shunt, prostatectomy, or nephrectomy, and in association with hematologic disorders (such as aplastic anemia), abruptio placentae (with laboratory confirmation of hyperfibrinolysis), hepatic cirrhosis, neoplastic disease, and polycystic or neoplastic diseases of the genitourinary system.